Back in at 3.2 myself as well.The buy/sell ratio is looking healthier by the minute - and given cash backing is nearly 3 cents, at this point it's pretty much a no brainer.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%